Trinity Biotech plc

NasdaqGS:TRIB Voorraadrapport

Marktkapitalisatie: US$11.5m

Trinity Biotech Toekomstige groei

Future criteriumcontroles 1/6

De verwachting is dat Trinity Biotech de winst en omzet met respectievelijk 33.2% en 11.8% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 55.6% per jaar.

Belangrijke informatie

33.2%

Groei van de winst

55.6%

Groei van de winst per aandeel

Medical Equipment winstgroei17.1%
Inkomstengroei11.8%
Toekomstig rendement op eigen vermogenn/a
Dekking van analisten

Low

Laatst bijgewerkt15 Nov 2024

Recente toekomstige groei-updates

Recent updates

Investors Give Trinity Biotech plc (NASDAQ:TRIB) Shares A 38% Hiding

Sep 25
Investors Give Trinity Biotech plc (NASDAQ:TRIB) Shares A 38% Hiding

A Piece Of The Puzzle Missing From Trinity Biotech plc's (NASDAQ:TRIB) 35% Share Price Climb

Aug 07
A Piece Of The Puzzle Missing From Trinity Biotech plc's (NASDAQ:TRIB) 35% Share Price Climb

The Market Lifts Trinity Biotech plc (NASDAQ:TRIB) Shares 34% But It Can Do More

Jun 11
The Market Lifts Trinity Biotech plc (NASDAQ:TRIB) Shares 34% But It Can Do More

Investors Don't See Light At End Of Trinity Biotech plc's (NASDAQ:TRIB) Tunnel And Push Stock Down 27%

Mar 02
Investors Don't See Light At End Of Trinity Biotech plc's (NASDAQ:TRIB) Tunnel And Push Stock Down 27%

Trinity Biotech plc's (NASDAQ:TRIB) Shares Bounce 31% But Its Business Still Trails The Industry

Dec 18
Trinity Biotech plc's (NASDAQ:TRIB) Shares Bounce 31% But Its Business Still Trails The Industry

A Look At The Fair Value Of Trinity Biotech plc (NASDAQ:TRIB)

Sep 12
A Look At The Fair Value Of Trinity Biotech plc (NASDAQ:TRIB)

Should You Investigate Trinity Biotech plc (NASDAQ:TRIB) At US$0.80?

Aug 08
Should You Investigate Trinity Biotech plc (NASDAQ:TRIB) At US$0.80?

Insufficient Growth At Trinity Biotech plc (NASDAQ:TRIB) Hampers Share Price

Jun 09
Insufficient Growth At Trinity Biotech plc (NASDAQ:TRIB) Hampers Share Price

Calculating The Intrinsic Value Of Trinity Biotech plc (NASDAQ:TRIB)

Apr 23
Calculating The Intrinsic Value Of Trinity Biotech plc (NASDAQ:TRIB)

This Broker Just Slashed Their Trinity Biotech plc (NASDAQ:TRIB) Earnings Forecasts

Apr 23
This Broker Just Slashed Their Trinity Biotech plc (NASDAQ:TRIB) Earnings Forecasts

Does Trinity Biotech (NASDAQ:TRIB) Have A Healthy Balance Sheet?

Mar 01
Does Trinity Biotech (NASDAQ:TRIB) Have A Healthy Balance Sheet?

Trinity Biotech appoints former GE executive Aris Kekedjian as CEO

Oct 03

At US$1.22, Is Trinity Biotech plc (NASDAQ:TRIB) Worth Looking At Closely?

Sep 01
At US$1.22, Is Trinity Biotech plc (NASDAQ:TRIB) Worth Looking At Closely?

Trinity Biotech GAAP EPADS of -50c, revenue of $18.78M misses by $1.22M

Jun 30

Winst- en omzetgroeiprognoses

NasdaqGS:TRIB - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/202678-8361
12/31/202569-15-11-81
12/31/202462-20-10-91
9/30/202459-20-16-7N/A
6/30/202459-22-14-8N/A
3/31/202457-34-15-12N/A
12/31/202357-37-14-12N/A
9/30/202371-39-13-10N/A
6/30/202354-46-8-5N/A
3/31/202374-34-7-2N/A
12/31/202263-44-7-1N/A
9/30/202276-32-62N/A
6/30/202279-22-53N/A
3/31/202286-13-26N/A
12/31/202181-2513N/A
9/30/2021106-81120N/A
6/30/2021116-21827N/A
3/31/2021106-21929N/A
12/31/2020102-61424N/A
9/30/202091-20-17N/A
6/30/202083-27-65N/A
3/31/202090-31-210N/A
12/31/201990-29-65N/A
9/30/201994-30-411N/A
6/30/201993-29-79N/A
3/31/201995-23-79N/A
12/31/201897-23-107N/A
9/30/201897-39-107N/A
6/30/201899-40N/A8N/A
3/31/201899-40N/A10N/A
12/31/201799-39N/A9N/A
9/30/201798-36N/A8N/A
6/30/201799-37N/A10N/A
3/31/2017100-36N/A8N/A
12/31/2016100-39N/A10N/A
9/30/20161013N/A17N/A
6/30/201610116N/A14N/A
3/31/20169816N/A13N/A
12/31/201510022N/A13N/A
9/30/201510123N/A15N/A
6/30/201510315N/A17N/A
3/31/201510517N/A16N/A
12/31/201410515N/A16N/A
9/30/201410318N/A8N/A
6/30/201410010N/A6N/A
3/31/20149510N/A8N/A
12/31/20139110N/A9N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat TRIB de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat TRIB de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat TRIB de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van TRIB ( 11.8% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van TRIB ( 11.8% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van TRIB naar verwachting over 3 jaar hoog zal zijn

Ontdek groeibedrijven

7D

1Y

7D

1Y

7D

1Y